Evidence item

The 95% disease-control estimate is from 40 enrolled participants at 12 South Korean sites, screened from 49, with 72.5% gallbladder-cancer representation and no prior treatment for advanced/metastatic disease. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25927

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:73577ef1fd04bfb5b6e7775c2facc5d5f72fc912d6a6fc4d71a4feae46641393

Between 12 May 2023 and 3 December 2024, 49 participants with known HER2-positive BTC were screened, with 40 enrolled across 12 sites in South Korea... All included participants were treatment-naive for advanced or metastatic diseases. The predominant cancer subtype was GBC (72.5%).